Pipeline
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Systemically Administered (RedTail) Delivered
CLD-401 (IL-15 SA)
Tumor-tropic genetic medicine that selectively lyses tumor cells, induces immune priming and transforms tumor cells into IL-15 superagonist (SA) producers for precise activation of anti-tumor immunity.
Indications
Stage
Multiple solid tumors
IND Enabling40%
40%
Genetic Payload: IL-15 Superagonist
CLD-501 (Undisclosed)
Precision targeting to myeloma and B-cells. Expresses an immunomodulatory genetic medicine payload.
Indications
Stage
Myeloma, autoimmune
Discovery10%
10%
Genetic Payload: Trop-2 In Situ TCE, IL-15 Superagonist
CLD-601 (Undisclosed)
Precision targeting to tumor cells (undisclosed target). Induces tumor lysis, immune priming, and expresses multiple payloads to precisely retarget T-cell activity against tumor cells.
Indications
Stage
Oncology (undisclosed)
Discovery5%
5%
Genetic Payload: Undisclosed
Intratumorally Delivered
NeuroNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion. Optimized for localized administration.
Indications
Stage
Rel/Ref glioblastoma
Phase 280%
80%
SuperNova
Oncolytic virus loaded into stem cells for enhanced potency and immune evasion for solid tumors. Optimized for intratumoral administration. Calidi Biotherapeutics does not currently have an expanded access program for our investigational product Supernova. Participation in our clinical trial is the only way to access Supernova at this time.
Indications
Stage
TNBC, SCCHN, Scarcoma
Phase 170%
70%
Press Releases
Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.